RayKnowChina Research Map
Shortlist0

RecruitingOesophageal squamous cell carcinomaPhase 3

Registered title, quoted from ClinicalTrials.gov

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07463573, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Has histologically or cytologically documented unresectable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) according to American Joint Committee on Cancer 8th edition staging system on ESCC.

    Inclusion criterion 9

  3. Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0 (v6.0);

    Inclusion criterion 8

    Having previously received B7-H3-targeted therapy.

    Exclusion criterion 7

    Having received treatment with systemic corticosteroids (prednisone at >10 mg/day, or similar drugs at equivalent dose) or other immunosuppressive agents within 14 days prior to randomization;

    Exclusion criterion 13

  4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 within 7 days before the first dose;

    Inclusion criterion 3

  5. Diagnosis of other primary malignancies within 5 years prior to signing the informed consent form.

    Exclusion criterion 1

  6. A serum pregnancy test must be performed within 7 days prior to randomization for premenopausal women of childbearing potential, and the result must be negative and must not be lactating;

    Inclusion criterion 5

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07463573, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntarily consent to participate in this study and sign the informed consent form.
  • Males and females aged ≥18 years old;
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 within 7 days before the first dose;
  • Estimated survival time of more than 3 months.
  • A serum pregnancy test must be performed within 7 days prior to randomization for premenopausal women of childbearing potential, and the result must be negative and must not be lactating;
  • All enrolled patients and the partners should take adequate barrier contraception during the entire treatment cycle and for 6 months after the end of treatment.
  • Capable of understanding trial requirements, willing and able to comply with trial and follow-up procedures.
  • Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0 (v6.0);
  • Has histologically or cytologically documented unresectable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) according to American Joint Committee on Cancer 8th edition staging system on ESCC.
  • Has at least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) as assessed by the investigator.
  • Sufficient bone marrow and organ function.

Exclusion Criteria:

  • Diagnosis of other primary malignancies within 5 years prior to signing the informed consent form.
  • Having histologically or cytologically confirmed adenosquamous carcinoma subtype.
  • Brain metastases (unless asymptomatic and no progression confirmed by imaging ≥4 weeks prior to randomization);
  • Presence of leptomeningeal metastases or brainstem metastases;
  • Spinal cord compression (identified via imaging, regardless of symptoms);
  • Previous or ongoing treatment with topoisomerase I inhibitors
  • Having previously received B7-H3-targeted therapy.
  • Being ineligible to any chemotherapies in the control arm due to prior progression or intolerance.
  • Insufficient washout of prior anticancer therapies prior to randomization.
  • Having underwent major organ surgery (excluding biopsy) or significant trauma within 4 weeks prior to randomization;
  • Requiring elective surgery during the study.
  • Having received live vaccine or live attenuated vaccine within 4 weeks before study randomization.
  • Having received treatment with systemic corticosteroids (prednisone at >10 mg/day, or similar drugs at equivalent dose) or other immunosuppressive agents within 14 days prior to randomization;
  • Moderate to severe pulmonary disease significantly impairing lung function, including idiopathic pulmonary fibrosis, autoimmune/connective tissue disorders with lung involvement, or prior pneumonectomy.
  • Having a history of interstitial lung disease (ILD)/ non-infectious pneumonitis that required corticosteroids, current ILD/ non-infectious pneumonitis, or suspected ILD/ non-infectious pneumonitis that cannot be ruled out by imaging at screening;
  • Active tuberculosis;
  • Autoimmune diseases not in clinical remission, other acquired or congenital immunodeficiency diseases,
  • A history of allogeneic stem cell, bone marrow, or organ transplantation.
  • Serious infections (e.g., bacteremia, or severe pneumonia) within 4 weeks prior to randomization;
  • active infection requiring systemic antibiotic therapy within 1 weeks prior to randomization;
  • Has positive results in virus serology tests (hepatitis B virus infection participants receiving antiviral treatment other than interferon are allowed to be enrolled);
  • Uncontrolled or significant cardiovascular disease.
  • Clinically uncontrolled third-space effusion.
  • Known hypersensitivity to investigational product components, analogues, or control drugs (e.g., docetaxel, paclitaxel, irinotecan hydrochloride).
  • Drug abuse;
  • Any other medical conditions that may interfere with study participation or the results of the clinical study as per the discretion of investigator;
  • Has alcohol or drug dependence.
  • Poor compliance as per investigator discretion;
  • Has a history of other serious systemic diseases.

Quoted from ClinicalTrials.gov, NCT07463573, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07463573, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07463573